Navigation Links
MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
Date:2/27/2008

- School-Based Vaccination Programs Using FluMist(R) May Serve as Model to

Help Vaccinate Large Numbers of Eligible Children -

GAITHERSBURG, Md, Feb. 27 /PRNewswire/ -- MedImmune, the manufacturer of FluMist(R) (Influenza Virus Vaccine Live, Intranasal), today lauded the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) for its unanimous vote to expand recommendations for routine seasonal influenza vaccination to include all school-age children up to the age of 18 years as soon as feasible but no later than the 2009-2010 influenza season. To support this move by the ACIP, MedImmune is preparing to manufacture a record number of FluMist doses -- about 12 million -- for the upcoming flu season, with the intention of continuing to substantially increase production in subsequent seasons.

"MedImmune applauds the ACIP for expanding its recommendations and stands ready to support this move by nearly tripling its production of FluMist doses for the 2008-2009 flu season," said Frank J. Malinoski, M.D., Ph.D., senior vice president of medical and scientific affairs.

"We also believe that positive experiences using FluMist in school-based programs point to the importance -- and opportunity -- of using non- traditional venues, in addition to traditional venues, to help achieve the goal of vaccinating a larger number of school-age children against the flu," added Malinoski.

Research has shown statistically significant reductions in influenza like illness (ILI), child doctors' office visits, medication use and work/school absenteeism among households whose children attended schools/daycares with influenza vaccination programs, compared to those whose children attended schools/daycares without these programs(1)(2).

Since introduction of the nasal spray vaccine to the U.S. market in 2003, FluMist has been increasingly utilized in schools, public health centers, and other c
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. MedImmune Expands Scientific and Engineering Leadership
2. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
3. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
7. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
8. Check Your Emergency Preparedness Kits When You Set Your Clocks, Says New American Public Health Association Campaign
9. TFAH Applauds Release of CDCs State-Specific Public Health Emergency Preparedness Report
10. K-State Trauma Researcher Says Being Prepared, Taking Action Are Vital in Preventing Tragedies Like the One at NIU
11. Many States Still Fall Short in Emergency Preparedness: Report

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... The award-winning docume...ision debut on the Sundance Channel on World Diabe... Directed by Academy Award® nominee Edward La...ith type 1 diabetes amid the verdant mountains and...t countries. The children are supported with life-...
(Date:11/9/2009)...9 Speaker Nancy Pelosi...ons in the Affordable Health Care for America ...id and reduce Medicare Part D costs for people liv...aturday by a vote of 220 to 215: ,, "Effective...lity of life for thousands of Americans living wit...
(Date:11/9/2009)...rt Experimental Procedure for Preteen Son - ,...For parents of children with cancer, the hopeful n... improved for decades. Among the bad news -- treat.... ,, Boys diagnosed with cancer who have reac...rve their fertility: before undergoing cancer trea...
(Date:11/9/2009)...l use funds to move lab findings into human therap...ain from nerve damage ,, ANN ARBOR, Mich., Nov... University of Michigan Department of Neurology ha...l therapy for neuropathic pain, a difficult-to-tre...ause of damage to nerve without obvious tissue inj...
(Date:11/9/2009)...r 9, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), th...y announced the availability of INTUNIV (guanfacin...he United States for the treatment of Attention-De...d adolescents ages 6 to 17. INTUNIV, a once-daily...nonscheduled alpha-2A receptor agonist approved fo...
Breaking Medicine News(10 mins):Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 2Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 3Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 4Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 5Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 6Health News:Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 4Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4
...mail intervention program is an effective way to s... helping people move more, sit less, and make heal...te Division of Research study in the American Jou...g 787 Kaiser Permanente Northern California employ...
...cancer bringing total raised by LIFE to $5.6 milli...ros including World Golf Hall of Fame members Beth... Stanford, Morgan Pressel, Brittany Lincicome, Hel...ast Cancer) Event hosted by LPGA veteran Val Skinn...
...ewswire-Asia-FirstCall/ -- BMP Sunstone,Corporatio...y"), today announced,financial results for the fir...Highlights from the First Quarter Ended March 31, ....7 million from $7.7 million in the prior, y...
...es, Inc. (Nasdaq: GTIV ), a leading provider of ... that on May 14, 2009 it received official notific...ce with the exchange,s independent director requir...ows: , , , until the earlier of the Com...
...ls, Inc. (Nasdaq: TRBN ) announced today that da...dy (15002) of TRU-015 for rheumatoid arthritis wil...gue Against Rheumatism (EULAR) annual meeting in C...TRUBIONLOGO ) , , Data from the first course of r...
...y Corporation, (Nasdaq: QG L Y), www.quigley...any,s possible alternative strategies going forwar...rding the unexpected positive finding for its QR-3...al are awaited, the Company,s Board of Directors a...
Other Medicine News:Health News:Workplace e-mail intervention program helps people sit less and eat better 2Health News:Workplace e-mail intervention program helps people sit less and eat better 3Health News:LIFE 10th Anniversary Event Delivers Big Names and Big Dollars for Breast Cancer Fight 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 3Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 4Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 5Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 6Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 7Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 8Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 9Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 10Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 11Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 2Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 2Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 4Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 2Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 3Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 4
(Date:11/9/2009)...INCETON JUNCTION, N.J., Nov. 9 Unw...edical devices, but recognizing today,s economic c...h quality aesthetic laser systems, introduces the ...priced at under $50,000. ,, The MOSAIC CO2 off...tional technology including scanning and stamping ...
(Date:11/9/2009)...N ARBOR, Mich., Nov. 9 Thomson R...cal Xpert(TM) CareFocus, a leading clinical survei... at-risk patients in real-time and respond immedia...cost of treatment. ,, This upgrade is available...ost. ,, CareFocus 2.0 contains several powerf...
(Date:11/9/2009)...NNYVALE, Calif., Nov. 9 ...eutical company focused on developing and commerci...eatment of immune mediated diseases and cancer, to..., Preclinical Development will provide an overview...man Curhan Ford,s 6th Annual Investor Summit. ,...
Breaking Medicine Technology:Lutronic(R) Unleashes the New MOSAIC CO2 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009 2Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress 14567 1Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress 14567 2Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress 14567 3CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women 5650 1CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women 5650 2CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women 5650 3CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women 5650 4Alzheimers lesions found in the retina 59918 1Alzheimers lesions found in the retina 59918 2
...30 Peptimmune, Inc. a privately,held biotechnolog...Number,7,381,790 (the ,790 patent) which protects ...copolymer for the treatment of autoimmune diseases...cending dose,double-blind, placebo-controlled rand...Following establishment of safety at potentially t...
... 30 Wound Care Innovations, LLC,a subsidiary of W...Board:,WNDM), announced today an evidence based st...ical performance of their advanced wound care coll...lcers. "According to data,released by the Centers ...ffects nearly 24 million people in the United Stat...
Other Medicine Technology:Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 2Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 3Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2
...nitoring System™ expands hospital-grade moni...ields of subacute care and disease state managemen...ss a full range of clinical applications, from con...e hospital, to periodic monitoring of patients out...
...ess capability to Welch Allyn's comprehensive hard...onitoring concept to provide vital signs data and ...xNet links multiple devices such as ambulatory wir...monitors to Acuity® Central Monitoring Station...
Wireless Propaq® CS
Vital Signs Monitor
Medicine Products: